132 related articles for article (PubMed ID: 8983270)
1. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
Bielack SS; Erttmann R; Kempf-Bielack B; Winkler K
Eur J Cancer; 1996 Sep; 32A(10):1652-60. PubMed ID: 8983270
[No Abstract] [Full Text] [Related]
2. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
3. Heart failure in a breast cancer survivor.
Moore S
Oncol Nurs Forum; 2012 Mar; 39(2):147-50. PubMed ID: 22374488
[No Abstract] [Full Text] [Related]
4. Doxorubicin for metastatic breast cancer: time for a change?
Muggia F
Cancer Invest; 2003; 21(6):967-8. PubMed ID: 14735701
[No Abstract] [Full Text] [Related]
5. Optimal schedule for anthracyclines.
Smith IE
Eur J Cancer Clin Oncol; 1985 Feb; 21(2):159-61. PubMed ID: 3857180
[No Abstract] [Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
8. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin in experimental and clinical heart failure.
Christiansen S; Autschbach R
Eur J Cardiothorac Surg; 2006 Oct; 30(4):611-6. PubMed ID: 16901709
[TBL] [Abstract][Full Text] [Related]
10. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
12. The anthracycline antineoplastic drugs.
Young RC; Ozols RF; Myers CE
N Engl J Med; 1981 Jul; 305(3):139-53. PubMed ID: 7017406
[No Abstract] [Full Text] [Related]
13. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
Jones WG; Mattsson W
Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
15. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity after liposomal anthracyclines.
Young AM; Dhillon T; Bower M
Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
[No Abstract] [Full Text] [Related]
17. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
[No Abstract] [Full Text] [Related]
18. An intertrigo-like eruption from pegylated liposomal doxorubicin.
Korver GE; Ronald H; Petersen MJ
J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
[TBL] [Abstract][Full Text] [Related]
19. [Acute cardiogenic postoperative edema after doxorubicin (adriamycin) chemotherapy].
Boulay G; Debaene B
Ann Fr Anesth Reanim; 1998; 17(1):43-6. PubMed ID: 9750682
[TBL] [Abstract][Full Text] [Related]
20. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
